

MechanoChemical Endovenous Ablation: A Tumescentless Technique

Steve Elias MD FACS FACPh
Director, Centers for Vein Disease
Mount Sinai NY and Englewood NJ Hospitals

Associate Professor of Surgery
Mount Sinai School of Medicine, NY

Disclosures


Consultant- Covidien
Consultant- Vascular Insights, LLC

**No AMA PRA Category 1 Credit™
will be given for this abstract.**

Words To Live By:

- Respect the elders,
- Embrace the new,
- Encourage the improbable and impractical
- Without bias


What Is It? ClariVein™



How Does It Work:

- **Combination** – endovenous and sclerotherapy
- **Endovenous** – wire > rotates > intima damage
- **Sclerosant** – liquid > penetrates > scar
- **End result** – venous occlusion


Mechanical Component



Chemical Component



Mechanico – Chemical Summary



APET: Steps of EVA

RF/Laser

- A - Access
- P - Position
- E - Exsanguinate
- T - Treat
- APET

ClariVein

- A - Access - **simpler**
- P - Position - **same**
- E - **No Tumescence**
- T - Treat - **faster**
- **APT**

Access: ClariVein

- Percutaneous ultrasound guided
- 4 fr. micropuncture sheath
- 18 gauge IV access
- No further wires or larger sheath exchange

Position: Wire exposed




Position: Wire 2 cm SFJ




Treat: ClariVein

- Pullback 1.0 – 1.5 mm. per second
- Inject during pullback
- Sodium tetradecyl sulfate 1.5% (or equivalent sclerosant)
- Injection rate limited by catheter lumen size (12cc of 1.5% STD)


Treat SFJ: Rotate and Inject



Treat Mid GSV: Wire/Sclerosant Mix



Treat: Injection & Pullback



Post Treatment: SFJ



Post Treatment:

- Compression X 48hrs
- Compression 2 weeks
- Full activity (exercise, lifting etc.)

Clinical Trial: ClariVein

- 30 limbs
- GSV only
- C2 – 24 C3 – 2 C4 – 4
- Avg. 55 years
- Treat GSV only (no treatment VV or IPV)
- 6 month follow up to complete trial
- No tumescence or sedation

Procedure Statistics: ClariVein

- GSV size – 8.1 mm.
- GSV length treated – 36 cm.
- GSV treatment time – 5 min.
- Overall treatment time - 14 min

Completed Trial - 6 Month F/U

- All GSV closed except 1st patient – competent
- 1 month – 30
- 3 month – 29/30
- 6 month – 29/30
- 12 month – 20/20

Complications

- Subcutaneous ecchymoses – 3 pts.
- Side branch tear?
- No DVT
- No nerve injury
- No skin injury

Thoughts: Real and Imagined

- Minimal risk – nerve, skin, DVT, discomfort
- Fast and simple – less steps
- Treat lower (ankle, calf, SSV)
- Some branch VV/ IPV treated at same time
- No tumescence or sedation
- No thermal injury risk
- No energy source - generator

Limitations:

- 30 patients
- Safety and efficacy
- Short term follow up (50 pts. more)
- Large veins > 12 mm. – not in trial (19mm)
- SSV – not done in trial

Perspective September 2009:

- Another good option
- Simpler
- Faster
- Capital cost less
- **Tumescentless** – already there
 - everyone else is trying
- "Foam rescue" – small segments recanalize
- Most GSV or SSV

Words To Live By:

- Respect the elders,
- Embrace the new,
- Encourage the improbable and impractical
- Without bias
